CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

Vectibix (panitumumab) use in cancer

Defines accepted indications, continuation rules, exclusions, and coding for panitumumab (Vectibix) for treatment of colorectal cancer and related off-label contexts; describes evidentiary sources required for authorization and administrative processing by Evolent for Neighborhood Health Plan of Rhode Island lines of business.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyVectibix (panitumumab) use in cancer

Policy CodePolicy N/A

Change TypeIndication added; template conversion; reference updates

Effective Date

Next Review Date

Key ActionSupport requests with FDA labeling, CMS compendia, NCCN/ASCO guidelines, or peer-reviewed literature meeting CMS standards; ensure documented KRAS/NRAS/BRAF test results for indicated uses.

POLICY UPDATE CHANGES

Converted to new Evolent guideline template and replaced prior UM ONC_1135 Vectibix (panitumumab) guidance; added new indication and updated references (February 2025).

Updated Evolent verbiage and continuation request verbiage; updated references (October 2024).

1Primary cancer indication (colorectal)

3Named combination partners listed

1HCPCS drug code provided

Policy Overview

This guideline defines accepted indications, continuation rules, exclusions, and coding for Vectibix (panitumumab) for the treatment of colorectal cancer and related off-label contexts for Neighborhood Health Plan of Rhode Island lines of business. Evolent is responsible for processing all medication requests from network ordering providers and enforces prior authorization; medications not authorized by Evolent may be deemed not approvable and not reimbursable.

The policy describes background, scope, and administrative processing: it applies to multiple lines of business (including Commercial, Medicaid, CHIP, Exchange/Marketplace, and Medicare Advantage) and establishes who is responsible for medication request processing. Continuation requests may be exempt from denial when specific continuation criteria are met (no disease progression on the medication, use within the last year without >30-day lapse of authorization, and no additional medications being added).

Status: CURRENT. Evolent updated this guidance when converting to the new Evolent guideline template (February 2025) and made prior administrative updates in October 2024; it continues to describe processing responsibilities and enforcement of continuation and exclusion criteria for Neighborhood Health Plan of Rhode Island.

Accepted Indications and Use Criteria (High-level)

Colorectal Cancer - Indications for Vectibix (panitumumab)

Vectibix is acceptable for members with specified disease and genetic status in any of the following settings:

ALL of the following

AND one of
- Member has KRAS/NRAS/BRAF wild-type disease and Vectibix will be used in combination with FOLFOX (fluorouracil, leucovorin, and oxaliplatin)
- Member has KRAS/NRAS/BRAF wild-type disease and Vectibix will be used in combination with FOLFIRI (fluorouracil, leucovorin, and irinotecan)
- Member has KRAS/NRAS/BRAF wild-type disease and Vectibix will be used as a single agent
- Member has KRAS/NRAS/BRAF wild-type disease and Vectibix will be used in combination with irinotecan for subsequent therapy following prior chemotherapy for metastatic disease
Capecitabine (Xeloda) may be substituted for 5-FU in the above 5-FU-based regimens (operational substitution allowance)

Continuation Requests Exemption Criteria

Continuation requests for a not-approvable medication shall be exempt provided ALL of the following are met:

ALL of the following

The member has not experienced disease progression on the requested medication
The requested medication was used within the last year without a lapse of more than 30 days of having an active authorization30 days
Additional medication(s) are not being added to the continuation request

Exclusion Criteria (Not acceptable)

Vectibix is not acceptable when ANY of the following exclusion criteria are present:

ANY of the following

Member has disease progression on Vectibix (panitumumab) or who has failed Erbitux (cetuximab)
Absence of documented KRAS/NRAS/BRAF testing and results of such testing for the above indications
Dosing exceeds single dose limit of Vectibix (panitumumab)single dose limit = 6 mg/kg
Investigational use of Vectibix with an off-label indication that is not sufficient in evidence or is not generally accepted by the medical community

Evidence Requirements and Sufficiency

Evidence Sufficiency Criteria for Off-label Uses

For off-label use to be considered sufficient it must meet CMS/compendia/peer-reviewed standards; assess ALL of the following evidence dimensions:

ALL of the following

Whether the clinical characteristics of the patient and the cancer are adequately represented in the published evidence
Whether the administered chemotherapy/biologic/immune/targeted/other oncologic therapy regimen is adequately represented in the published evidence
Whether the reported study outcomes represent clinically meaningful outcomes experienced by patients (ASCO guidance: e.g., hazard ratio < 0.80 and OS/PFS benefit >= 3 months as a general benchmark)HR < 0.80; OS/PFS >= 3 months
Whether the experimental design is appropriate to address the investigative question (randomization, blinding, etc., as contextually appropriate)
Non-randomized trials with significant subject numbers may be supportive
Case reports and meeting abstracts without full peer-reviewed articles generally lack adequate supportive evidence

The evidence base cited includes multiple peer-reviewed randomized and non-randomized trials, ASCO and NCCN guidance, the Vectibix prescribing information, and drug information resources such as Clinical Pharmacology and Micromedex, with citations listed from 2023–2025. The brief identifies specific literature (including randomized phase trials and the 2023 NEJM report of sotorasib plus panitumumab) and updated prescribing information and compendia through 2025.

For off-label uses to be considered sufficient, the policy requires documentation that evidence meets CMS/compendia/peer-reviewed standards and the CMS Medicare Benefit Policy Manual Chapter 15 criteria; published evidence must represent the patient and regimen, show clinically meaningful outcomes (ASCO benchmarks), and have appropriate study design or substantial subject numbers.

Sufficient evidence — definition

TermSufficient evidence

DefinitionEvidence supported by CMS-recognized compendia or acceptable peer-reviewed literature; considers representativeness, regimen representation, clinically meaningful outcomes (ASCO benchmarks), and study design appropriateness.

Key componentsRepresentativeness of patient and cancer characteristics; regimen representation in published evidence; clinically meaningful outcomes (ASCO: e.g., HR < 0.80 and OS/PFS benefit ≥ 3 months); appropriate experimental design; non-randomized trials with significant subjects may be supportive; case reports and abstracts alone generally lack adequate support.

Actions Required & Billing/Authorization Notes

Prior Authorization

Evolent authorization required for reimbursement

Evolent must authorize medication requests for reimbursement; medications not authorized by Evolent may be deemed not approvable and not reimbursable.

J9303

Documentation Required

Evidence supporting therapy required

Requests must be supported by FDA-approved labeling, CMS-recognized compendia, NCCN/ASCO clinical guidelines, or peer-reviewed literature that meets CMS Medicare Benefit Policy Manual Chapter 15 standards. Absence of documented KRAS/NRAS/BRAF testing and results for the indicated uses is exclusionary.

Absence of documented KRAS/NRAS/BRAF test results is exclusionary
J9303

Denial Risk

Denial for prior progression or cetuximab failure

Claims may be denied when the member has experienced disease progression on Vectibix (panitumumab) or has failed cetuximab (Erbitux).

J9303

Billing Rule

Dose limit enforcement

Dosing that exceeds the single dose limit of 6 mg/kg is an exclusion and is subject to denial or non-coverage.

J9303
Single dose limit = 6 mg/kg

Background and Policy Context

The policy defines accepted indications for panitumumab that include FDA-approved uses for advanced or metastatic colorectal cancer with appropriate RAS/BRAF status and specified chemotherapy backbones (FOLFOX, FOLFIRI, or single-agent use), with capecitabine allowed as an operational substitute for 5-FU in 5-FU-based regimens. It also includes some off-label combination uses cited in the brief: Vectibix in combination with encorafenib (Braftovi) for BRAF V600E–mutant unresectable/metastatic disease and Vectibix combined with sotorasib (Lumakras) for KRAS G12C–mutated metastatic colorectal cancer after prior standard chemotherapy.

Evidentiary support for these off-label combinations must meet CMS-recognized compendia or acceptable peer-reviewed literature standards (assessed using representativeness, regimen representation, clinically meaningful outcomes per ASCO benchmarks, and study design appropriateness). This policy applies to Neighborhood Health Plan of Rhode Island lines of business and Evolent is responsible for processing medication requests and enforcing continuation and exclusion criteria for authorization and reimbursement.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyVectibix (panitumumab) use in cancer

Policy CodePolicy N/A

Change TypeIndication added; template conversion; reference updates

Effective Date

Next Review Date

Key ActionSupport requests with FDA labeling, CMS compendia, NCCN/ASCO guidelines, or peer-reviewed literature meeting CMS standards; ensure documented KRAS/NRAS/BRAF test results for indicated uses.

On This Page

OpenPayer

Vectibix (panitumumab) use in cancer

Policy Overview

Accepted Indications and Use Criteria (High-level)

Evidence Requirements and Sufficiency

Relevant Codes

Actions Required & Billing/Authorization Notes

Background and Policy Context

Policy Revision History